10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2010 | |||
STATEMENTS OF OPERATIONS | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 17, 2011) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Revenues | |||
| Sanofi-aventis collaboration revenue | $ 311,332 | 247,140 | 153,972 |
| Other collaboration revenue | 75,393 | 67,317 | 31,166 |
| Technology licensing | 40,150 | 40,013 | 40,000 |
| Net product sales | 25,254 | 18,364 | 6,249 |
| Contract research and other | 6,945 | 6,434 | 7,070 |
| Total Revenues | 459,074 | 379,268 | 238,457 |
| Expenses | |||
| Research and development | 489,252 | 398,762 | 274,903 |
| Selling, general, and administrative | 65,201 | 52,923 | 48,880 |
| Cost of goods sold | 2,093 | 1,686 | 923 |
| Total Expenses | 556,546 | 453,371 | 324,706 |
| Loss from operations | (97,472) | (74,103) | (86,249) |
| Other income (expense) | |||
| Investment income | 2,122 | 4,488 | 18,161 |
| Interest expense | (9,118) | (2,337) | (7,752) |
| Loss on early extinguishment of debt | 0 | 0 | (938) |
| Total Other Income (Expense) | (6,996) | 2,151 | 9,471 |
| Net loss before income tax expense | (104,468) | (71,952) | (76,778) |
| Income tax (benefit) expense | 0 | (4,122) | 2,351 |
| Net loss | (104,468) | (67,830) | (79,129) |
| Net loss per share, basic and diluted | (1.26) | (0.85) | (1.00) |
| Weighted average shares outstanding, basic and diluted | 82,926 | 79,782 | 78,827 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2010 | |||
STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 17, 2011) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Cash flows from operating activities | |||
| Net loss | $ (104,468) | (67,830) | (79,129) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | |||
| Depreciation and amortization | 19,687 | 14,247 | 11,287 |
| Non-cash compensation expense | 39,897 | 31,259 | 32,523 |
| Loss on early extinguishment of debt | 0 | 0 | 938 |
| Net realized loss (gain) on marketable securities | 293 | (56) | 1,310 |
| Changes in assets and liabilities | |||
| Increase in accounts receivable | (27,544) | (30,356) | (16,892) |
| Decrease (increase) in prepaid expenses and other assets | 2,723 | (4,574) | (6,560) |
| Increase (decrease) in deferred revenue | 158,151 | (27,497) | (26,834) |
| Increase (decrease) in accounts payable, accrued expenses, and other liabilities | 7,605 | 12,577 | (5,729) |
| Total adjustments | 200,812 | (4,400) | (9,957) |
| Net cash provided by (used in) operating activities | 96,344 | (72,230) | (89,086) |
| Cash flows from investing activities | |||
| Purchases of marketable securities | (605,124) | (199,997) | (581,139) |
| Sales or maturities of marketable securities | 276,601 | 297,411 | 646,861 |
| Purchases of restricted marketable securities | (7,063) | 0 | 0 |
| Decrease (increase) in restricted cash | 1,122 | 50 | (50) |
| Capital expenditures | (99,689) | (97,318) | (34,857) |
| Net cash (used in) provided by investing activities | (434,153) | 146 | 30,815 |
| Cash flows from financing activities | |||
| Repurchases or repayment of notes payable | 0 | 0 | (200,807) |
| Proceeds in connection with facility lease obligation | 47,544 | 23,640 | 0 |
| Payments in connection with facility lease obligation | (924) | (875) | 0 |
| Net proceeds from the issuance of Common Stock | 196,790 | 8,598 | 7,949 |
| Payments in connection with capital lease obligation | (104) | 0 | 0 |
| Net cash provided by (used in) financing activities | 243,306 | 31,363 | (192,858) |
| Net decrease in cash and cash equivalents | (94,503) | (40,721) | (251,129) |
| Cash and cash equivalents at beginning of period | 207,075 | 247,796 | |
| Cash and cash equivalents at end of period | 112,572 | 207,075 | 247,796 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | 12,737 | 2,525 | 9,348 |
| Cash paid for income taxes | 0 | 0 | 3,079 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2010 | ||
BALANCE SHEETS | ||
Period Ending Dec 31, 2010 10-K (Filed: Feb 17, 2011) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2010 | Dec 31, 2009 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $ 112,572 | 207,075 |
| Marketable securities | 136,796 | 134,255 |
| Accounts receivable from the sanofi-aventis Group | 79,603 | 62,703 |
| Accounts receivable - other | 13,509 | 2,865 |
| Prepaid expenses and other current assets | 15,142 | 18,610 |
| Total current assets | 357,622 | 425,508 |
| Restricted cash and marketable securities | 7,518 | 1,600 |
| Marketable securities | 370,053 | 47,080 |
| Property, plant, and equipment, at cost, net of accumulated depreciation and amortization | 347,450 | 259,676 |
| Other assets | 6,789 | 7,338 |
| Total assets | 1,089,432 | 741,202 |
| LIABILITIES and STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | 53,658 | 49,031 |
| Deferred revenue from sanofi-aventis, current portion | 19,506 | 17,523 |
| Deferred revenue - other, current portion | 35,217 | 27,021 |
| Facility lease obligations, current portion | 675 | 0 |
| Total current liabilities | 109,056 | 93,575 |
| Deferred revenue from sanofi-aventis | 97,081 | 90,933 |
| Deferred revenue - other | 188,775 | 46,951 |
| Facility lease obligations | 159,355 | 109,022 |
| Other long term liabilities | 7,350 | 3,959 |
| Total liabilities | 561,617 | 344,440 |
| Commitments and contingencies | ||
| Stockholders' equity | ||
| Preferred stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding-none | 2 | 2 |
| Common Stock | 87 | 79 |
| Additional paid-in capital | 1,575,780 | 1,336,732 |
| Accumulated deficit | (1,045,563) | (941,095) |
| Accumulated other comprehensive (loss) income | (2,491) | 1,044 |
| Total stockholders' equity | 527,815 | 396,762 |
| Total liabilities and stockholders' equity | 1,089,432 | 741,202 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |